Crystalys Therapeutics appoints Justin Thacker as CFO to aid Phase 3 trials of Dotinurad in gout treatment.
On January 21, 2026, in San Diego, Crystalys Therapeutics, Inc. disclosed the appointment of Justin Thacker as part of their initiative to cater to the medical requirements of individuals affected by gout. Crystalys, a company in the clinical-stage biopharmaceutical sector, aims to address the pressing needs of those living with gout. This move signifies a step towards fulfilling their objectives in this field.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments